Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VYGR Voyager Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VYGR
Price (delayed)
$3.3
Market cap
$182.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.47
Enterprise value
$146.98M
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation
Highlights
Voyager Therapeutics's quick ratio has increased by 10% from the previous quarter and by 8% YoY
The company's debt fell by 4% QoQ
The revenue is down by 39% year-on-year and by 24% since the previous quarter
VYGR's gross profit is down by 39% year-on-year and by 24% since the previous quarter
Key stats
What are the main financial stats of VYGR
Market
Valuations
Earnings
Shares outstanding
55.34M
Market cap
$182.61M
Enterprise value
$146.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
3.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.43
Revenue
$60.49M
Gross profit
$60.49M
Operating income
-$108.27M
Net income
-$84.69M
EBIT
-$84.01M
EBITDA
-$78.24M
Free cash flow
-$114.01M
Per share
Balance sheet
Liquidity
EPS
-$1.47
EPS diluted
-$1.47
Free cash flow per share
-$1.95
Book value per share
$4.94
Revenue per share
$1.04
TBVPS
$6.05
Total assets
$353.24M
Total liabilities
$80.54M
Debt
$42M
Equity
$272.7M
Working capital
$204.99M
Debt to equity
0.15
Current ratio
6.1
Quick ratio
5.99
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-129.3%
Gross margin
100%
Net margin
-140%
Operating margin
-179%
Return on assets
-21.1%
Return on equity
-27.4%
Return on invested capital
-28.5%
Return on capital employed
-26.8%
Return on sales
-138.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYGR stock price
How has the Voyager Therapeutics stock price performed over time
Intraday
0.61%
1 week
4.1%
1 month
5.43%
1 year
-61.76%
YTD
-41.8%
QTD
-2.37%
Financial performance
How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$60.49M
Gross profit
$60.49M
Operating income
-$108.27M
Net income
-$84.69M
Gross margin
100%
Net margin
-140%
The operating income has dropped by 196% year-on-year and by 30% since the previous quarter
The operating margin has plunged by 72% from the previous quarter
The company's net margin has shrunk by 72% QoQ
The revenue is down by 39% year-on-year and by 24% since the previous quarter
Price vs fundamentals
How does VYGR's price correlate with its fundamentals
Growth
What is Voyager Therapeutics's growth rate over time
Valuation
What is Voyager Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
3.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.43
Voyager Therapeutics's EPS has decreased by 30% from the previous quarter
VYGR's price to book (P/B) is 68% lower than its 5-year quarterly average of 2.1 and 33% lower than its last 4 quarters average of 1.0
VYGR's equity is down by 20% year-on-year and by 9% since the previous quarter
The revenue is down by 39% year-on-year and by 24% since the previous quarter
VYGR's price to sales (P/S) is 12% less than its 5-year quarterly average of 3.6 and 3.6% less than its last 4 quarters average of 3.3
Efficiency
How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's ROS has plunged by 73% from the previous quarter
Voyager Therapeutics's return on assets has decreased by 40% QoQ
VYGR's return on equity is down by 38% since the previous quarter
Voyager Therapeutics's ROIC has decreased by 28% from the previous quarter
Dividends
What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYGR.
Financial health
How did Voyager Therapeutics financials performed over time
The total liabilities has contracted by 37% YoY and by 14% from the previous quarter
VYGR's total assets is down by 25% year-on-year and by 10% since the previous quarter
The company's debt is 85% lower than its equity
VYGR's equity is down by 20% year-on-year and by 9% since the previous quarter
The company's debt fell by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.